^
Association details:
| Biomarker: | Chr t(11;14)(q13;q32) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | carfilzomib (Proteasome inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
Excerpt:
Patient 2 was a 48-year-old Saudi man with International Staging System stage III immunoglobulin G kappa multiple myeloma with t(11,14)(q13;q32) diagnosed in May 2017….Eighteen months later, he had disease progression, and he received multiple lines of chemotherapy, including carfilzomib/dexamethasone. He was shifted to venetoclax/carfilzomib/dexamethasone...
Secondary therapy:
dexamethasone
DOI:
10.1186/s13256-020-02376-y
